RetroSense Therapeutics, LLC
RetroSense is developing a gene therapy for vision restoration in retinal degenerative conditions, for which there are no approved drugs.
RetroSense is developing a novel gene therapy approach to vision restoration. Our management team has extensive experience across all aspects of the business and science of drug development, including multiple startup successes. Based on optogenetics, our approach is validated in vision restoration across multiple species, with excellent safety data. As a gain-of-function approach, efficacy is expected early in clinical trials.